Cellectar receives orphan drug designation for clr 131 in lymphoplasmacytic lymphoma

Cellectar receives orphan drug designation for clr 131 in lymphoplasmacytic lymphoma (lpl).cellectar biosciences - fda has granted orphan drug designation to clr 131 in lymphoplasmacytic lymphoma.
CLRB Ratings Summary
CLRB Quant Ranking